Wu H Y
Cancer Hospital, Shanghai University of Medical Sciences.
Zhonghua Zhong Liu Za Zhi. 1988 Sep;10(5):335-8.
173 simultaneous determinations of serum copper level (SCL), serum zinc level (SZL) and copper/zinc ratio (CZR) were made by atomic absorption spectrophotometry in 51 previously untreated lymphoma patients. SCL and CZR were significantly higher in patients before treatment (mean value 146.33 micrograms/dl, 1.55) and in those who did not reach complete remission (mean 135.29 micrograms/dl, 1.36) as compared with the patients in complete remission (mean 104.30 micrograms/dl, 1.06) or normal controls (mean 99.82 micrograms/dl, 0.98). The mean value of SCL and CZR of patients in complete remission did not differ significantly from those of normal controls. Patients in stages III and IV had higher SCL and CZR (mean 160.22 micrograms/dl, 1.79) than those in Stages I and II (mean 122.95 micrograms/dl, 1.16). No significant difference was observed in SZL between the patients groups and normal controls. Thus, SCL and CZR may be used as prognostic indicators for monitoring disease activity and response to therapy in malignant lymphoma.
采用原子吸收分光光度法对51例未经治疗的淋巴瘤患者同时进行血清铜水平（SCL）、血清锌水平（SZL）及铜/锌比值（CZR）的测定。与完全缓解患者（均值104.30微克/分升，1.06）或正常对照组（均值99.82微克/分升，0.98）相比，治疗前患者（均值146.33微克/分升，1.55）及未达到完全缓解的患者（均值135.29微克/分升，1.36）的SCL和CZR显著更高。完全缓解患者的SCL和CZR均值与正常对照组无显著差异。Ⅲ期和Ⅳ期患者的SCL和CZR（均值160.22微克/分升，1.79）高于Ⅰ期和Ⅱ期患者（均值122.95微克/分升，1.16）。各患者组与正常对照组之间的SZL无显著差异。因此，SCL和CZR可用作监测恶性淋巴瘤疾病活动及治疗反应的预后指标。
